American scientists from University of California at Los Angeles found that the drug, created to treat completely different diseases, effectively slows down the progression of Parkinson's disease. These findings were made on the basis of observations of laboratory mice.
The exact cause of Parkinson's disease unknown, but Some data suggest that the disease develops due to accumulation alpha-synuclein. Higher doses of the protein are found in all victims disease. As scientists believe, alpha-synuclein kills neurons in the brain, producing the neurotransmitter dopamine, which helps regulate some part functions including movement and coordination. Deficiency of dopamine is associated with the presence of Parkinson's disease.
Gaucher disease is a rare genetic disorders related to lysosomal diseases which It develops when the body can not produce enough of the enzyme β-glyukotseribrozidazy. US researchers watched what genetic factors that increase the risk of developing Parkinson's disease. They determined that there are some similarities between Gaucher disease and Parkinson's. Mutation of the gene, leads to reduced activity β-glyukotseribrozidazy in the brain, it is a genetic risk factor in Parkinson's disease. However, most patients with this disease have a mutation in their body Gaucher gene.
The findings allow suggests that formulations designed for therapy of Gaucher disease may be effective in treating Parkinson's disease. Currently, this disease It considered incurable, but some drugs from a group capable of levodopa slow it down for. Alas, their effect noted not all patients, and many patients Parkinson's disease It progresses quite rapidly, thus depriving them of mobility and independence. (READ MORE)
Industry News
Go back to the main page
No comments:
Post a Comment